Chris S. Pridgeon
Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms
Pridgeon, Chris S.; Schlott, Constanze; Wong, Min Wei; Heringa, Minne B.; Heckel, Tobias; Leedale, Joe; Launay, Laurence; Gryshkova, Vitalina; Przyborski, Stefan; Bearon, Rachel N.; Wilkinson, Emma L.; Ansari, Tahera; Greenman, John; Hendriks, Delilah F. G.; Gibbs, Sue; Sidaway, James; Sison-Young, Rowena L.; Walker, Paul; Cross, Mike J.; Park, B. Kevin; Goldring, Chris E. P.
Authors
Constanze Schlott
Min Wei Wong
Minne B. Heringa
Tobias Heckel
Joe Leedale
Laurence Launay
Vitalina Gryshkova
Stefan Przyborski
Rachel N. Bearon
Emma L. Wilkinson
Tahera Ansari
Professor John Greenman J.Greenman@hull.ac.uk
Professor of Tumour Immunology
Delilah F. G. Hendriks
Sue Gibbs
James Sidaway
Rowena L. Sison-Young
Paul Walker
Mike J. Cross
B. Kevin Park
Chris E. P. Goldring
Abstract
The development of improved, innovative models for the detection of toxicity of drugs, chemicals, or chemicals in cosmetics is crucial to efficiently bring new products safely to market in a cost-effective and timely manner. In addition, improvement in models to detect toxicity may reduce the incidence of unexpected post-marketing toxicity and reduce or eliminate the need for animal testing. The safety of novel products of the pharmaceutical, chemical, or cosmetics industry must be assured; therefore, toxicological properties need to be assessed. Accepted methods for gathering the information required by law for approval of substances are often animal methods. To reduce, refine, and replace animal testing, innovative organotypic in vitro models have emerged. Such models appear at different levels of complexity ranging from simpler, self-organized three-dimensional (3D) cell cultures up to more advanced scaffold-based co-cultures consisting of multiple cell types. This review provides an overview of recent developments in the field of toxicity testing with in vitro models for three major organ types: heart, skin, and liver. This review also examines regulatory aspects of such models in Europe and the UK, and summarizes best practices to facilitate the acceptance and appropriate use of advanced in vitro models.
Citation
Pridgeon, C. S., Schlott, C., Wong, M. W., Heringa, M. B., Heckel, T., Leedale, J., Launay, L., Gryshkova, V., Przyborski, S., Bearon, R. N., Wilkinson, E. L., Ansari, T., Greenman, J., Hendriks, D. F. G., Gibbs, S., Sidaway, J., Sison-Young, R. L., Walker, P., Cross, M. J., Park, B. K., & Goldring, C. E. P. (2018). Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms. Archives of Toxicology, 92(2), 557-569. https://doi.org/10.1007/s00204-018-2152-9
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 27, 2017 |
Online Publication Date | Jan 23, 2018 |
Publication Date | 2018-02 |
Deposit Date | Apr 9, 2019 |
Publicly Available Date | Apr 10, 2019 |
Journal | Archives of Toxicology |
Print ISSN | 0340-5761 |
Publisher | Springer (part of Springer Nature) |
Peer Reviewed | Peer Reviewed |
Volume | 92 |
Issue | 2 |
Pages | 557-569 |
DOI | https://doi.org/10.1007/s00204-018-2152-9 |
Keywords | 3D in vitro models; Heart; Skin; Liver |
Public URL | https://hull-repository.worktribe.com/output/1566797 |
Publisher URL | https://link.springer.com/article/10.1007%2Fs00204-018-2152-9 |
Contract Date | Apr 9, 2019 |
Files
Published article
(2.2 Mb)
PDF
Copyright Statement
© The Author(s) 2018
Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
You might also like
Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells
(2023)
Presentation / Conference Contribution
Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment
(2023)
Presentation / Conference Contribution
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search